A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells

Area of Science:

• Immunology
• Cell Biology
• Cancer Research

Background:

• Natural killer (NK) cells are crucial for immune surveillance, identifying and eliminating abnormal cells.
• NK cell activity is regulated by surface receptors that distinguish healthy from cancerous cells.

Purpose of the Study:

• To engineer NK cells with enhanced cancer-killing capabilities using a novel receptor construct.
• To evaluate the efficacy of these engineered NK cells against various cancer types and in preclinical models.

Main Methods:

• Designed and introduced a chimeric receptor (NKG2D-DAP10-CD3ζ) into NK cells via retroviral transduction.
• Assessed NK cell cytotoxicity against leukemia and solid tumor cell lines, and against normal cells.
• Investigated signal transduction pathways, cytokine secretion, and cytotoxic granule release upon receptor stimulation.
• Evaluated in vivo antitumor activity in a mouse model of osteosarcoma.

Main Results:

• Engineered NK cells exhibited significantly increased surface NKG2D expression and enhanced cytotoxicity against cancer cells, but not normal cells.
• NKG2D blockade abolished the enhanced cancer cell killing.
• Receptor stimulation led to robust signal transduction, cytokine/chemokine secretion (IFN-γ, TNF-α, etc.), and sustained cytotoxic granule release.
• NKG2D-DAP10-CD3ζ-expressing NK cells demonstrated significant antitumor effects in vivo.

Conclusions:

• The NKG2D-DAP10-CD3ζ receptor enhances NK cell-mediated cancer cell killing and antitumor immunity.
• This engineered NK cell strategy shows promise for broad-spectrum cancer immunotherapy.
• Development of an electroporation method facilitates clinical translation for generalized cellular therapy.